by akronbiotech

A Letter From Our CEO

Dear Valued Partner,

In challenging and uncertain times, it’s our collective responsibility to take care of one another. At Akron Biotech, our top priority is always our customers and our staff. That’s why we are closely monitoring the COVID-19 situation around the clock, ensuring that we take all necessary precautions to keep our staff safe and our facilities clear of any risks related to the coronavirus. This includes adhering to recommendations from the CDC, the WHO, and other global health authorities.

We are leveraging our secure platforms and communication tools to maximize flexibility. We remain fully operational and will keep you updated as the situation continues to evolve. More than ever, we remain steadfast in our belief in the importance of ensuring the safety and integrity of the therapies we are working together to advance. For this reason, we have adopted additional security measures in all of our manufacturing processes and are prioritizing the use of virus inactivated raw materials in our human blood-derived products, including our sera, plasma, and fibronectin.

As always, thank you for trusting Akron Biotech for your ancillary material needs. Every day, we work together to find treatments and cures to the world’s most complicated illnesses. If this unprecedented climate is any indication, our work is more important than ever.

We are here for you.

Claudia Zylberberg, Ph.D.
Chief Executive Officer
Akron Biotechnology

Leave A Comment